# Council memo — 2026-08-18

*Structured synthesis of this system's own agents' analysis. Not advice from a
licensed advisor. Sources read this sweep: `data/cache/snapshots/20260818T113223.json`
(and `20260817T111313.json` for the move column), `data/cache/screens/20260818T113405-digest.csv`
(all 67 rows, all three statuses), `data/portfolio.json`, `data/investor_profile.json`,
`data/cache/definitions.json`, `data/cache/excel_import/latest-summary.json`,
`OPEN_ITEMS.md`, plus this session's market-data / valuation / macro-regime /
portfolio / thesis-review / scout / calendar outputs.*

`journal` ran in session-start mode at the top of this session. Its reconciliation
of last sweep's calls is a separate end-of-sweep artifact in `SESSION_LOG.md` — not
blocked on here.

**Blocking-question check.** No open item currently holds blocking status.

**Candidate universe: 76 names.** 9 current holdings with a ticker or distinct
identity (SHB-A.ST, INVE-A.ST, VOLV-B.ST, ATCO-B.ST, AZN.ST, ALFA.ST, ABB.ST,
ethereum, Valour Bitcoin Zero) + the two index funds + all 67 watchlist entries
from `scout`'s digest across **all three** statuses (15 Passed, 19 Missing-data,
33 Failed). Cash, the tax reserve and the frozen SEB Osteuropafond are excluded —
no buy/sell decision exists for them. COIN-XBT.ST is closed and excluded.

> **Method change you should know about, because it changes an outcome.**
> `council.md` was revised 2026-08-17 (after that day's test memo) on two points:
> diversification is no longer a seventh stock-picking voice — it is `portfolio`'s
> job, consulted once at the Chairman stage — and **overlap with a broad index
> fund you already hold is explicitly no longer a reason to de-prioritise a name.**
> Yesterday's test memo killed eleven candidates (GOOGL, META, MSFT, NVDA and
> others) purely on Avanza Global overlap. Under the current rule they are back in
> contention, and one of them is this memo's #2. That is a deliberate reversal by
> your own instruction, not an inconsistency.

---

## 1. Position report

Snapshot `20260818T113223.json` · previous `20260817T111313.json`

> **Provenance note.** This run had no shell access, so the table below is
> arithmetic on the two named snapshots using `position_report.py`'s own
> conventions (price, move vs previous sweep, move vs cost basis, true
> low-to-high 52-week percentile). It reconciles **exactly** to the portfolio
> agent's independently-computed full-portfolio total of ~219,031 SEK, which is
> the cross-check. Re-run the script next sweep.

| Position | Price | Δ vs last sweep | Δ vs cost | 52w percentile | Value (SEK) | Source |
|---|---|---|---|---|---|---|
| Handelsbanken A (1 sh) | 148.40 | +0.1% | **+14.8%** | **96.0%** | 148.40 | fetched |
| Investor A (5 sh) | 406.30 | -0.1% | **+40.0%** | 91.1% | 2,031.50 | fetched |
| Volvo B (13 sh) | 342.70 | +0.7% | **-6.8%** | 75.5% | 4,455.10 | fetched |
| Atlas Copco B (27 sh) | 180.55 | -0.3% | -0.4% | 91.3% | 4,874.85 | fetched |
| **AstraZeneca (5 sh)** | **1,489.00** | **+0.6%** | **-1.4%** | **22.1%** | 7,445.00 | fetched |
| Alfa Laval (9 sh) | 558.80 | +0.3% | -2.7% | 80.5% | 5,029.20 | fetched |
| ABB (4 sh) | 974.20 | +0.3% | +2.9% | 80.8% | 3,896.80 | fetched |
| Avanza Auto 3 (fund) | no data | — | +65.2% | — | 16,191.00 | book value (NAV 2026-07-24) |
| Avanza Global (fund) | no data | — | +0.0% | — | 119,999.00 | book value |
| ETH (0.50185, self-custody) | 18,113.60/unit | **+0.7%** | no data (**P1**) | — | 9,090.30 | fetched (1,644.30 EUR × sek_per_eur 11.016) |
| Valour Bitcoin Zero (150 u) | **no price feed (S1)** | — | +0.0% (at cost) | — | 9,183.00 | user-reported cost, 61.22/unit |
| Avanza ISK cash | — | — | — | — | 11,183.00 | computed, see capital check |
| HB tax reserve + checking | — | — | — | — | 11,363.76 | confirmed |
| PayPal (1,177.49 USD + 266.88 EUR) | — | — | — | — | 14,140.30 | confirmed, pending P3 conversion |

**Full portfolio 219,031 SEK** (full-portfolio convention, `data/cache/definitions.json`).
Equity look-through **71.95%** · crypto **8.34%** · cash **16.75%**.
BTC 55,556 EUR (-48.4% off ATH), ETH 1,644.30 EUR (-61.1% off ATH), Fear & Greed
**41** ("Fear", up from 31 yesterday).

**Reading it.** Nothing moved enough to matter. All seven stocks moved under 1%
and ETH +0.7% in SEK (only +0.1% in EUR — **more than half of that move is the
krona weakening against the euro**, sek_per_eur 10.9523 → 11.016, not ethereum
doing anything). The index funds are deliberately buy-and-hold, both INTACT, one
line each is the right amount of attention. **No move contradicts a thesis this
sweep.** Two positional facts are worth carrying forward, and both are unchanged
rather than new: AstraZeneca remains the only holding below its cost basis and
the only one in the bottom quartile of its own year (22.1st percentile) with
every fundamental input intact — price moved, information did not; and
Handelsbanken A sits at 96.0% of its range on revenue -3.8% YoY, PEG 20.4 and an
analyst "underperform", i.e. the upside its original thesis named has been taken.
The four industrials remain clustered at 75-91% of range, which is the
concentration story, not seven separate stories.

---

## 2. Top opportunities — Stock Selection Council

### Step 0 — triage (what each voice actually looked at)

Each voice filtered all 67 digest rows on its own named fields before writing
anything. Three data-quality findings came out of that pass and constrain what
follows — they are stated here once rather than repeated per pick:

1. **The digest has no currency column, and `fcf_b` is not on a consistent
   currency basis with `mcap_b`.** Ericsson (30.71 FCF / 317 mcap = 9.7%) is
   plausible; Alphabet (22.67 / 4,207 = 0.5%) and TSMC (730.83 / 2,235 = 33%)
   are not — the market caps look USD-converted while the cash-flow figures are
   in the reporting currency. **Consequence: the FCF-yield proxy the Valuation
   voice is supposed to use in place of a missing EV/EBIT is unusable this
   sweep** except where currency is confirmed identical. Named, not worked
   around.
2. **The digest carries no 52-week range.** That is the Contrarian voice's
   primary triage field for non-held names, so its "near a 52-week low" screen
   ran only on the seven holdings (from the position report). Every
   contrarian pick below is therefore argued from multiples and status, not from
   drawdown — which is a weaker basis and is scored accordingly.
3. **No `sek_per_dkk` in the macro block** (again — same blocker as yesterday).
   Novo Nordisk and Vestas cannot be priced or sized in SEK from fetched data.
   Not a reason to exclude them; it is a reason no order can be written.

### Step 1 — six independent passes

*Each voice reviewed the full 76-name universe and wrote before seeing any other
voice's conclusions. Convictions were not adjusted afterwards for consistency.*

---

#### Voice 1 — Fundamental / Quality Investor
*Triage fields: `roe_pct`, `roic_pct`, `margin_pct`, `net_debt_to_ebitda`, `fcf_b`.*

**BUY 1 — GOOGL (Alphabet). Conviction 8.**
Profit margin 54.8%, ROE 48.7%, ROIC 28.6%, net cash (net debt/EBITDA -0.70), and
revenue still growing 24.2% at a 4.2-trillion-USD market cap. On the five fields I
screen, nothing else in this universe is close on all five simultaneously. *Why
now, not generically:* the combination of a still-accelerating top line with a
balance sheet carrying no net debt is what lets a business absorb a heavy
investment cycle without financing risk — which is precisely the objection being
levelled at it. *Key risks / what invalidates:* if the current AI capex build is a
permanent margin reset rather than a cycle, the 54.8% margin is the number that
falls, and it is the whole pick. A regulatory remedy forcing structural separation
would do the same. *Missing data, named:* no multi-year FCF/capex series anywhere
in this system (structural Yahoo limit); profit margin 54.8% exceeding operating
margin means the bottom line contains something non-operating I cannot see; and
per the triage note, the FCF figure is not comparable to the market cap. Confidence
discounted by roughly one point on that. *Excel request:* 4-year free cash flow and
capex for GOOGL.

**BUY 2 — NOVO-B.CO (Novo Nordisk B). Conviction 7.**
Profit margin 35.3%, ROE 59.8%, ROIC 35.6%, net debt/EBITDA 0.55, FCF 37.67bn
against a 1,284bn market cap (same currency here — DKK both sides — so ~2.9% FCF
yield is usable). This is the best non-US business in the universe on returns on
capital. **It carries a FAIL status from `scout` on PEG 3.11 alone** — a
growth-adjusted measure, failing because trailing growth stalled to +2.1%, not
because anything in the quality record broke. That is a threshold measuring the
wrong window for a company mid-patent-cycle, and I am naming it rather than
deferring to it. *Key risks:* if +2.1% is the slope rather than a trough, the
quality is intact and the price is merely fair. D/E 63.3 is the highest among my
picks. *Missing data:* no sek_per_dkk (cannot size); no pipeline, patent-expiry or
competitive data of any kind — for a pharma whose growth just stalled, that is the
specific thing I would need. *Excel request:* a SEK/DKK rate, and 4-year revenue
for NOVO-B.CO.

**BUY 3 — EPI-B.ST (Epiroc). Conviction 6.**
ROIC 29.7%, ROE 21.2%, profit margin 14.2%, net debt/EBITDA 0.81, revenue +10.4%.
The best Nordic-industrial quality profile in the watchlist and — this is the
point — measurably better on growth and leverage than two of the four industrials
already held (ALFA revenue +7.7%, ABB net-debt-heavier per its own review). *Why
now:* if the industrial sleeve is going to be 65% of the stock book, the question
of *which* industrials is live regardless of whether the sleeve shrinks. *Key
risks:* forward P/E 37.96 against trailing 28.97 — consensus expects earnings to
**fall**, which is the single strongest argument against my own pick, and mining
capex is a narrower cycle than general industrial capex. *Missing data:* no
multi-year revenue pulled for it this sweep (digest-only read).

**Honourable, not picked:** MSFT (margin 40.3%, ROE 34.0%, ROIC 20.7%) is a
genuinely top-4 business here; it did not make three because Epiroc's marginal
information value to *this* book is higher and I only get three.

**SELL — SHB-A.ST. Conviction 5.**
ROE 12.7%, ROA 0.63%, revenue -3.8% with the reported fiscal series declining from
62.3bn (2024) to 56.8bn (2025). Nothing in the quality data supports holding it.
Honest limit: it is one share worth 148.40 SEK, so this is an attention decision,
not a return decision.

---

#### Voice 2 — Valuation Investor
*Triage fields: `pe`, `fwd_pe`, `peg`, `div_yield_pct`, and — where currency is
confirmed consistent — `fcf_b` against `mcap_b`. **This system has no EV/EBIT and
no direct FCF-yield field**; everything below that resembles one is an
approximation and is labelled as such.*

**BUY 1 — GOOGL. Conviction 7.**
Trailing P/E 17.27, PEG 0.94, on 24.2% revenue growth and 54.8% margins. A
sub-1.0 PEG on the highest-quality large-cap in the universe is the single
cleanest risk-adjusted proposition on this screen. *Why now:* forward P/E 23.33
sits **above** trailing 17.27, and I want to be explicit that this is the one
mark against the price — consensus expects reported earnings to step down, most
plausibly on depreciation from the capex build. I still rank it first because a
0.94 PEG absorbs a considerable step-down before the multiple stops being
attractive. *Key risks:* if the forward multiple is right and the trailing one is
flattered by non-operating items, I am paying 23x, not 17x. *Missing data:* no
EV/EBIT; the FCF-yield proxy is unusable here (triage note 1); no fair-value
estimate anywhere in this system (V2 Phase 2 unbuilt).

**BUY 2 — META. Conviction 6.**
P/E 21.41 falling to a **forward 16.31**, PEG 0.88, on 28.0% revenue growth with
net debt/EBITDA 0.20. Forward below trailing is consensus saying earnings are
rising — the opposite signature to GOOGL's, and it is the reason this is a
separate pick rather than a duplicate of it. *Key risks:* the same capex question,
one notch more acute; beta 1.243. *Missing data:* as above, plus no multi-year
capex series to test whether the spend is cyclical.

**BUY 3 — TTE (TotalEnergies). Conviction 4 — deliberately low, and I want the
reason recorded.** P/E 11.05, forward **9.19**, PEG 0.72, dividend 4.78% — on
headline numbers the cheapest defensible name in the Passed list. **But this
sweep's digest reports revenue growth of +27.8%, while last sweep's full-JSON
multi-year series for the same company showed four consecutive declining fiscal
years.** I cannot reconcile those from the data I have, and the entire "cheap
multiple on a growing business" case depends on which is right. A 4 is the honest
number for a pick whose central fact is in dispute. *Key risks:* if revenue is in
fact declining, an 11x P/E on an integrated oil major is a permanent sector
feature (terminal-value uncertainty), not a signal. *Missing data:* no reserve
life, no breakeven oil price, no capex plan — and now a direct internal
inconsistency on revenue direction. *Excel request:* 3-year revenue history for
TTE and EQNR, to settle the direction.

**Where quality and price pull apart, stated rather than averaged:**
- **ATCO-B.ST** (held): a top-tier business (Voice 1's lens) at P/E 32.6, PEG
  2.38, 91.3% of range. Great company, not a great entry.
- **ALFA.ST** (held): PEG **2.86** — the worst growth-adjusted value of the three
  P6 industrials *despite* the lowest headline P/E, because its growth is lower.
- **HEXA-B.ST**: trailing P/E 10.85 is the lowest in the Passed list and I am
  **explicitly rejecting it** — forward P/E 17.68 is 63% higher, which means the
  trailing figure contains something non-recurring. Cheap on the wrong number.

**SELL — ABB.ST. Conviction 6.** P/E 36.80 with forward P/E **36.19 — essentially
flat — while revenue grew 14.2%.** The market is pricing zero earnings growth out
of double-digit revenue growth; that is margin compression expressed as a
multiple. PEG 2.71, 80.8% of range. *Missing data, named:* Yahoo's raw P/S (48.4x)
and P/B (108.9x) for ABB are FX-unit artifacts — use the corrected ~5.2x / ~11.7x
in `data/company_profiles/ABB.ST.json`, not the snapshot's raw figures.

**SELL — SHB-A.ST. Conviction 5.** PEG 20.4 at 96.0% of range on a shrinking top
line. A 12.4x P/E that is cheap for a reason.

---

#### Voice 3 — Growth / Opportunity Investor
*Triage fields: `rev_growth_pct`, `fwd_pe` vs `pe`, `peg`. **No TAM, no earnings
revisions, no market-share data exists anywhere in this system** — "growth" below
means measured revenue growth and forward-multiple compression only. Any
commentary beyond that is qualitative reasoning from the business description and
is labelled.*

**BUY 1 — META. Conviction 7.**
Revenue +28.0%, PEG 0.88, and P/E compressing 21.41 → **16.31** forward. That
combination — high measured growth *and* a cheapening forward multiple — occurs
exactly once in this 76-name universe among large caps. *Why now:* the forward
multiple moved in the direction that matters while the growth rate stayed high;
that is a live signal, not a standing quality statement. *Key risks:* the forward
figure is consensus estimate, not fact; one quarter of ad-revenue deceleration
re-rates it. *Missing data:* no segment revenue, no user metrics, no capex plan.

**BUY 2 — NVDA. Conviction 6 — arguing explicitly past a FAIL.**
`scout` failed it on trailing P/E 34.46 > 30.0. That threshold is calibrated for
steady-state businesses and is measuring the wrong window here: revenue grew
**85.2%**, PEG is **0.62**, and the forward P/E is **17.53 — roughly half
trailing**. A static trailing-P/E cap will mechanically reject every business
whose earnings are growing faster than its multiple, which is the entire category
this voice exists to find. *Key risks:* beta 2.215, and the whole case rests on
consensus forward estimates I cannot verify; a single quarter of order
deceleration removes it. *Missing data:* no order book, no backlog, no customer
concentration — for a name whose case is forward trajectory, a serious gap, and
it is why this is a 6 and not an 8.

**BUY 3 — VWS.CO (Vestas). Conviction 4 — genuinely 4, not padded.**
Revenue +26.1%, PEG 0.85, forward P/E 16.95 vs trailing 24.83, net debt/EBITDA
-0.04 (roughly net-cash). *Key risks, which are why it is a 4:* profit margin
5.4% and ROIC **4.5%** — this is growth without returns on capital, and D/E 89.2
means the growth is partly financed. *Missing data:* no order intake, which for a
turbine manufacturer is the number that actually leads revenue; no sek_per_dkk.

**Named caution on a name others like — AMZN.** Passed the screen, revenue
+19.6%, but forward P/E **25.12 against trailing 21.14**: consensus expects
earnings down. I am not picking it and the forward/trailing inversion is why.

**On the existing book.** VOLV-B.ST is the only holding with a live growth
inflection: the fiscal series fell from 552.8bn (2023) to 526.8bn (2024) to
479.2bn (2025) — **two consecutive annual declines, -13.3% from the peak** — while
trailing revenue growth has now flipped to **+2.7%** with forward P/E 13.76 and an
analyst "buy". Held two weeks against its own three-month break condition. I flag
the inflection and recommend nothing.

**SELL: none.** No holding fails on growth grounds in a way another lens does not
cover better.

---

#### Voice 4 — Defensive / Risk Analyst
*Triage fields: `de_ratio`, `net_debt_to_ebitda`, `beta`, `margin_pct`.*

**What I am actually worried about.** DXY 118.90 with Fed funds 3.63% against
Riksbank 1.75% and ECB 2.25%; US CPI 3.54% against that 3.63% policy rate is a
**real policy rate of about +0.1%** — barely restrictive, so inflation
re-acceleration is a live risk, not a closed one. VIX 14.25 is complacency, not
calm. And the portfolio-specific risk is not macro at all: **65.5% of the
individual-stock sleeve is one bet on the global capex cycle**, with zero energy,
zero staples, zero telecom and one healthcare name. My job is to name what should
be owned if that goes wrong, not only to object.

**BUY 1 — AZN.ST (existing holding, add). Conviction 7.**
Beta **0.211** — the lowest of anything held — at the 22.1st percentile of its
52-week range, below its own cost basis, with revenue rising four consecutive
fiscal years (44.4 → 45.8 → 54.1 → 58.7bn) and operating margin 23.5%. *Why now,
specifically:* buying volatility protection is cheapest when volatility is cheap,
and VIX 14.25 is cheap. *Key risks / what invalidates:* the holding's own recorded
break conditions — structural margin deterioration, a dividend cut, or a re-rating
to a growth-like premium. None triggered this sweep. *Missing data:* Yahoo's raw
P/S (37.9x) and P/B (46.2x) for AZN show the same currency-mismatch signature as
ABB — unusable, and not part of my case.

**BUY 2 — UNH (UnitedHealth). Conviction 6.**
Beta 0.632, net debt/EBITDA 1.57, D/E 69.2, and forward P/E **17.63 against
trailing 25.44** — consensus expecting earnings to recover from a compressed base.
Healthcare demand is the least income-elastic large sector available here. *Key
risks, and they are real:* profit margin **3.1%** is genuinely thin, which means
small changes in medical cost ratio swing earnings hard; revenue growth +0.4% is
a stall; and US healthcare policy risk is not quantifiable from any data this
system holds. *Missing data:* no medical-loss-ratio or reserve-development data —
for an insurer that is the core operating metric and it is absent.

**BUY 3 — ERIC-B.ST (Ericsson). Conviction 5.**
Net debt/EBITDA **-0.41 (net cash)**, beta 0.504, D/E 37.7, dividend 3.09%, ROE
26.1%, and it is SEK-denominated so it carries no FX-translation risk for this
investor. *Key risks:* revenue **-6.1%** — this is balance-sheet defence, not
growth defence, and I am not pretending otherwise; telecom capex cycles are long
and currently against it.

**Named and rejected, on the record — TEL2-B.ST.** Beta 0.323 and a **6.38%
dividend** is a textbook ballast profile that will pass any yield screen. Forward
P/E **25.18 against trailing 11.49** says the market expects earnings to roughly
halve; PEG 4.31; D/E 135.2. That is a dividend-trap signature, not defence. Same
rejection as last sweep, same reason, and it recurs because the yield keeps
attracting the screen.

**SELL — ABB.ST. Conviction 6.** Highest beta of the three P6 industrials
(1.011), richest multiple, thinnest cash conversion (FCF margin ~4.4% per its own
review), and the single largest contributor to the concentration I am most worried
about.

**Risk flagged without a sell — VOLV-B.ST.** D/E **147.3** is the highest leverage
in the book by a wide margin, against a two-year revenue decline that has only
just inflected. I am not recommending a sale two weeks into a three-month break
condition, but this is the position that gets hurt worst if the capex cycle turns.

*Missing data that would most change my assessment:* **revenue-by-currency for
every holding.** The scorecard's currency row is UNKNOWN and, in a DXY-119 regime,
how much of the industrial sleeve's earnings are USD-translated is exactly what I
cannot see. *Excel request:* a currency-of-revenue or at least
currency-of-listing column per holding.

---

#### Voice 5 — Contrarian / Risk Taker
*Triage fields: low `pe`/`fwd_pe`/`peg` combined with a FAIL or MISSING status;
52-week position. **The digest carries no 52-week range**, so the drawdown half of
my screen ran only on held names — every pick below is weaker for it.*

**BUY 1 — NOVO-B.CO. Conviction 7.**
The market has taken a business with 59.8% ROE, 35.6% ROIC and 35.3% margins to a
**P/E of 11.06 with a 4.0% dividend**, and this system's own screen then failed it
— on PEG alone. *Specifically why the pessimism looks overdone rather than merely
loud:* the de-rating is priced off one stalled trailing year (+2.1%) against four
years of compounding, and a 11x multiple on a 35%-margin franchise requires
permanent impairment to be correct, not merely slower growth. *And the specific
thing that says I might be wrong, which I am not hiding:* forward P/E **13.25 is
above trailing 11.06** — consensus expects earnings to actually fall, so I am
betting against the estimate, not just against sentiment. That is a harder bet and
it is why this is a 7 and not a 9. *Missing data:* no sek_per_dkk (cannot size);
no 52-week range in the digest, so I cannot state how beaten down it currently is;
no pipeline data.

**BUY 2 — UNH. Conviction 6.**
Trailing P/E 25.44 on a **3.1% margin** is not cheap — but that margin is the
compressed one, and the forward P/E of 17.63 says consensus agrees it is
compressed rather than structural. Buying a business at a cyclical margin trough
priced as though the trough is permanent is the trade this voice exists for. *Why
it might be wrong:* if US medical cost inflation is a step-change rather than a
cycle, a 3.1% margin has very little cushion before it is negative.

**BUY 3 — AZN.ST (held). Conviction 5.**
It is the only holding in the bottom quartile of its own 52-week range (22.1%),
below cost, on four straight years of rising revenue. A contrarian holds this; a
contrarian adds to it modestly. I rank it third only because the pessimism here is
mild, not extreme — this is not a name anyone hates.

**Explicitly rejected despite screening well — HEXA-B.ST (Hexagon).** Trailing P/E
10.85 is the cheapest number in the entire Passed list and would normally be my
first look. Forward P/E 17.68 is 63% higher, which means the trailing earnings
contain something non-recurring. Cheap on a number that is not repeating is not a
contrarian opportunity, it is a measurement error.

**SELL — INVE-A.ST. Conviction 4.**
Not a view on Investor as a business. It sits at 91.1% of its 52-week range, the
"good upside" its recorded thesis named has been captured, and the one metric that
could tell you whether it is still attractive — NAV discount/premium — **has never
been obtained (S6)**. The 4.73x P/E is a holding-company accounting artifact, not
cheapness. My honest position: this is the opposite of a contrarian holding — it
is a crowded one I cannot measure. Conviction 4 because "I can't measure it" is a
reason to be uncomfortable, not a reason to be confident.

---

#### Voice 6 — Macro / Regime Analyst
*Working from `macro-regime`'s output plus the snapshot's macro block; sector and
currency exposure from the digest. **No commodity-price and no credit-spread data
is fetched by this system** — nothing below rests on either.*

**Regime read.** Neutral with a live risk-off tilt **specifically against crypto**.
10y-2y spread **+0.51** (positively sloped, no recession signal), VIX **14.25**,
real Fed funds ~+0.09%. Against that, DXY **118.90** — extreme USD strength, and
historically the mechanical headwind for crypto; Fear & Greed 41 corroborates.
**Advantaged now:** low-beta defensives (volatility is cheap), SEK-denominated
earners (no translation exposure for this investor), energy as the one real-asset
hedge if the near-zero real policy rate lets inflation re-accelerate.
**Disadvantaged:** crypto explicitly; and long-duration high-multiple USD assets
if the 10-year (4.68%, up from 4.63%) keeps rising.

**BUY 1 — AZN.ST. Conviction 6.** Beta 0.211 into VIX 14.25 is the asymmetry worth
owning when protection is cheap, and it is SEK-listed so there is no
buy-at-peak-dollar problem. Stated plainly: **this is the easy case — macro and
company fundamentals agree.**

**BUY 2 — ERIC-B.ST. Conviction 5.** SEK-denominated, net cash, beta 0.504, 3.09%
yield. In a regime where I cannot confidently grade the Swedish industrial cycle
(see the data gap below), a net-cash Swedish balance sheet is the version of
domestic exposure that survives being wrong about the cycle.

**BUY 3 — TTE. Conviction 5.** Energy is the one sector positively levered to the
single shock (inflation re-acceleration at a ~+0.1% real policy rate) that would
hit the equity sleeve *and* the crypto sleeve at once, and the portfolio holds
none. *Stated limit:* I have **no commodity-price data**, so this is a structural
hedging argument, not a view on oil.

**Regime downgrade of fundamentally strong names, said out loud as the method
requires.** GOOGL, META and NVDA have the strongest company fundamentals in this
universe. I am marking all three down purely because they are high-multiple,
long-duration, **USD-priced assets bought with SEK at DXY 118.90** — you are
taking the currency risk on top of the equity risk at an extreme level of the
currency. **That is a macro override of good fundamentals and should be read as
exactly that**, not as a doubt about the businesses. If you disagree with the
regime read, discard the downgrade; the fundamental case is untouched.

**SELL: none on regime grounds — including crypto.** The crypto sleeve is squarely
on the wrong side of this regime and I still do not recommend selling it: Fear &
Greed 41 is mild fear rather than capitulation (it has *improved* from 31), the
stated horizon is 3y+, and this system has no demonstrated short-horizon timing
edge. Regime should govern sizing, not liquidation.

*Missing data that most caps me:* **Swedish CPI is stale at period 2025M12 — now
8 months old (S4).** I cannot compute a real Swedish policy rate, which means I
cannot honestly regime-grade **59.3% of the portfolio's geography and 65.5% of the
individual-stock sleeve**. **This is the third consecutive sweep this single gap
has capped a live call.** *Excel request:* nothing Excel can fix — this is a
fetcher change (S4).

---

### Step 2 — the Chairman: Top 5 Overall Opportunities

*Ranked by how much the evidence says each deserves your attention this sweep —
buys and sells both. Where a voice's stated motivation does not survive contact
with the numbers, I say so rather than averaging it in.*

**Capital-availability premise check, done once, against this sweep's own
portfolio-agent output.** Avanza ISK cash reads **11,183 SEK** and the portfolio
agent confirms it is **still idle** — the AZN.ST buy this Council called yesterday
**did not execute** (AZN.ST still at quantity 5, no new lot). Two caveats that
change how much of it you should treat as spendable:
- Of the 11,183, only **~6,183 SEK traces cleanly** (15,366 COIN-XBT.ST sale
  proceeds − 9,183 Valour purchase). The other **5,000 SEK entered via an Excel
  delta whose source S9 flags as undocumented**. If it is the external transfer
  you described, it is real; if not, the free figure is 6,183.
- **D4 (undecided) governs how much of it is free at all.** Under reading 1
  (target governs sizing; recycling governs only surplus above target) all 11,183
  is free, because crypto is now *under* target at 8.34%. Under reading 3
  (realized gain only) 3,266 SEK is committed to the secure tier and ~7,917
  remains. Under reading 2 (gross proceeds) nothing is free — and that reading
  also implies your own Valour purchase was non-compliant, which your direct
  action outranks. **Every call below is sized to survive readings 1 and 3.**
- PayPal's 14,140 SEK is real but not yet liquid: P3 is decided, pending your
  execution, at a confirmed ~4% conversion cost (≈13,575 SEK net).

```
#1 OPPORTUNITY: AZN.ST — AstraZeneca
TYPE: existing holding — 5 shares, 7,445 SEK, 3.40% of portfolio
AGENTS IN FAVOR: Defensive/Risk: 7, lowest beta in the book (0.211) at the 22.1st
        percentile of its own range with volatility cheap at VIX 14.25;
        Macro/Regime: 6, SEK-listed defensive that macro and fundamentals agree
        on — the easy case; Contrarian: 5, the only holding in the bottom
        quartile of its year, below cost, on four straight rising revenue years
AGENTS AGAINST / CAUTIOUS: none. Fundamental/Quality, Valuation and Growth each
        ranked other names higher but **not one voice argued against it**. Stated
        plainly because it is uncommon: genuinely one-sided across six lenses.
STRONGEST CASE FOR: Defensive/Risk's, because it is the only argument here that
        is time-sensitive rather than perennial — beta 0.211 is worth most when
        implied volatility is cheapest, and VIX 14.25 with a real policy rate near
        zero is a specifically cheap moment to buy protection you also want to own
        on fundamentals.
STRONGEST CASE AGAINST: nobody made one, so I will. "Price down, thesis intact" is
        exactly what a value trap looks like from the inside. The distinguishing
        test is whether fundamentals moved with the price — and they did not:
        revenue +6.4% across four consecutive rising fiscal years, operating
        margin 23.5%, payout 47.4%, PEG 1.34. The objection is answerable and
        answered. The residual risk is information not in this snapshot.
DATA GAPS: No fair-value estimate (V2 Phase 2 unbuilt). Yahoo's raw P/S 37.9x and
        P/B 46.2x are currency-mismatch artifacts — unusable, and not part of the
        case, which rests on P/E, PEG, beta, four-year revenue and range
        percentile, all clean. Discount: minimal.
CHAIRMAN CONVICTION: 8
MAJOR UNCERTAINTY: Whether the 22.1st-percentile price reflects information this
        system cannot see. The holding's own break conditions are the control.
FINAL CALL: BUY — 3 shares at ~1,489 SEK ≈ 4,467 SEK. **Re-affirms yesterday's
        unexecuted call**; it did not go stale, the price moved +0.6%.
PORTFOLIO-FIT REASONING: Per `portfolio` this sweep: sector concentration is ACT
        (industrials 65.48% of the stock sleeve), geography ACT (Sweden 59.32%),
        equity 71.95% vs an 85% target (-13.05pp). This is the only executable
        purchase that improves three graded dimensions at once — it raises equity,
        and it grows the non-industrial and non-Swedish-revenue denominator (AZN
        is Swedish-listed but a UK company, so it dilutes sector concentration
        cleanly and geography partially). Takes the position to 8 shares, ~11,912
        SEK, ~5.4% of the portfolio: inside the 15% single-position cap and inside
        the 3-8% "normal" band. Funded from ISK cash — survives D4 readings 1 and
        3. Wrapper: ISK, no tax event, ~115k SEK of allowance headroom.
        `portfolio` also newly flags the individual-stock sleeve as **100%
        large-cap with zero mid/small-cap** — this buy does not help that, and I
        am not pretending it does.
HORIZON: Medium (6mo-3y) for the entry; the holding's own stated horizon is 3-5y
```

```
#2 OPPORTUNITY: GOOGL — Alphabet
TYPE: new candidate (not currently held)
AGENTS IN FAVOR: Fundamental/Quality: 8, the strongest five-field profile in the
        universe — 54.8% margin, 48.7% ROE, 28.6% ROIC, net cash, +24.2% revenue;
        Valuation: 7, PEG 0.94 on a 17.27x trailing P/E is the cleanest
        risk-adjusted proposition on the screen
AGENTS AGAINST / CAUTIOUS: Macro/Regime: explicit downgrade — a high-multiple,
        long-duration, USD-priced asset bought with SEK at DXY 118.90, i.e. you
        take currency risk at an extreme on top of equity risk; Growth: did not
        pick it — forward P/E 23.33 above trailing 17.27 means consensus expects
        reported earnings to step down; Defensive/Risk: did not pick it — beta
        1.237 and a capex cycle it cannot size
STRONGEST CASE FOR: Fundamental/Quality's, and it is stronger than Valuation's
        because it does not depend on an estimate. A 54.8% profit margin, 48.7%
        ROE and a net-cash balance sheet are reported facts; the 0.94 PEG depends
        on a growth figure that could decelerate. When the quality case and the
        price case point the same way, take the one built on filed numbers.
STRONGEST CASE AGAINST: Macro/Regime's, and it is a genuine constraint rather than
        a quibble — but note precisely what it is and is not. It is **not** an
        argument that Alphabet is a worse business or a worse price. It is an
        argument that a SEK investor converting at DXY 118.90 is buying two risks
        and only being paid for one. That is real, it is unhedgeable in this
        portfolio, and it is the reason this is #2 rather than #1.
DATA GAPS: (1) No multi-year FCF/capex series anywhere in this system — the exact
        thing that would settle whether the capex build is a cycle or a permanent
        margin reset, which is the whole bear case. (2) The digest's FCF figure is
        not on the same currency basis as its market cap, so no FCF yield can be
        computed. (3) No fair-value estimate. Together: discount confidence by
        about one and a half points.
CHAIRMAN CONVICTION: 7
MAJOR UNCERTAINTY: Is the AI capex build a cycle or a permanent step-change in
        the cost base? The forward-above-trailing P/E says consensus already
        assumes some of the latter. No fetchable data resolves it.
FINAL CALL: BUY — approximately 2 shares (345.90 USD × sek_per_usd 9.5121 ≈ 3,290
        SEK/share, ≈ 6,580 SEK). **Execution note: no capital is confirmed free
        for this after #1 under D4 reading 3.** Fund it from the PayPal conversion
        once P3 executes (≈13,575 SEK net), or from the next monthly contribution.
        This is a call on the investment merit; the funding is a separate question
        and is not a reason to bury the call.
PORTFOLIO-FIT REASONING: Per `portfolio`: communication services is 0% of the
        individual-stock sleeve, non-Nordic individual equity is 0%, and Sweden is
        59.32% (ACT). This is the largest single reduction in both the sector and
        the geography concentration available in the universe. **Note the rule
        change:** overlap with Avanza Global — which killed this name outright in
        yesterday's test memo — is explicitly no longer a de-prioritisation
        reason per your own revised `council.md`, so the fit case now stands on
        the concentration numbers alone. Two counterweights, both real: it adds
        USD currency exposure the scorecard cannot measure (currency row UNKNOWN),
        and it does nothing for the newly-surfaced 100%-large-cap gap. Sized at
        ~6,580 SEK it would be ~3.0% of the portfolio, inside every cap.
HORIZON: Long (3y+)
```

```
#3 OPPORTUNITY: ABB.ST — ABB
TYPE: existing holding — 4 shares, 3,896.80 SEK, 1.78% of portfolio
AGENTS IN FAVOR: none. Not one of the six voices picked ABB as a buy at any
        conviction, for the second consecutive sweep.
AGENTS AGAINST / CAUTIOUS: Valuation: 6 SELL, forward P/E 36.19 essentially flat
        against trailing 36.80 *while revenue grew 14.2%* — margin compression
        expressed as a multiple; Defensive/Risk: 6 SELL, highest beta of the three
        P6 industrials and the largest contributor to the ACT-rated
        concentration; Fundamental/Quality: implicit — FCF margin ~4.4%, the worst
        cash conversion in the book, undercutting the 32.6% ROE
STRONGEST CASE FOR (holding): none of the six made one. The case for holding comes
        from outside this method and is a **discipline** argument, not a view on
        ABB: the holding's own `break_conditions`, written 2026-08-17 from real
        Finansinspektionen data, require the insider-selling cluster to continue
        into a **second** FI pull before hardening into an active reduce. That was
        the first pull, and **no new FI data was pulled this sweep**, so the
        condition has not been tested, let alone met.
STRONGEST CASE AGAINST: Valuation's, and it matters because it never touches the
        insider signal. A forward multiple flat against trailing while revenue
        grows 14.2% means the market prices zero earnings growth out of
        double-digit revenue growth. Combined with ~4.4% FCF conversion, the price
        requires an improvement the cash flow does not show. This case is
        independent of the break condition the discipline argument protects.
DATA GAPS: Raw P/S 48.4x and P/B 108.9x are FX-unit artifacts — use the corrected
        ~5.2x / ~11.7x in `company_profiles/ABB.ST.json`. No multi-year FCF series
        to test whether 4.4% is structural or one heavy capex year. No second FI
        insider pull. These lower confidence but not direction: P/E, forward P/E
        and revenue growth are all clean.
CHAIRMAN CONVICTION: 6 that it is the weakest holding; 4 that selling it *this
        week* is right
MAJOR UNCERTAINTY: Whether the ~4.4% FCF margin is a capex cycle or a structural
        conversion problem. A real multi-year FCF series settles it and this
        system cannot fetch one — it needs ABB's own cash flow statement via the
        `pdf` skill.
FINAL CALL: HOLD-WATCH — with a hard date, not an open-ended watch
PORTFOLIO-FIT REASONING: Per `portfolio`, ABB is the most redundant name in an
        industrials sleeve already at 65.48% (ACT). One fact cuts the other way
        and deserves stating: **inside an ISK a rotation is nearly frictionless**
        — no capital-gains event, only courtage — so the usual "selling is
        expensive, hold" argument does not apply here, and the honest reason this
        is HOLD-WATCH rather than SELL is the untested break condition, not
        transaction cost. Two concrete unblocks: (a) **run the next FI insider
        pull before 2026-09-03** — if the selling cluster continued, this
        converts to SELL and ABB becomes the funding source for #2; (b) if you
        adopt the valuation case instead, it stands on its own and does not need
        the FI data. At 1.78% of the portfolio this belongs folded into the next
        order round, never as a standalone trip.
HORIZON: Medium (6mo-3y)
```

```
#4 OPPORTUNITY: NOVO-B.CO — Novo Nordisk B
TYPE: new candidate (not currently held) — carries a FAIL status from scout
AGENTS IN FAVOR: Fundamental/Quality: 7, best returns-on-capital profile outside
        the US mega-caps (ROE 59.8%, ROIC 35.6%, margin 35.3%, net debt/EBITDA
        0.55); Contrarian: 7, an 11.06x P/E with a 4.0% yield on a 35%-margin
        franchise requires permanent impairment to be correct, not merely slower
        growth
AGENTS AGAINST / CAUTIOUS: Growth: did not pick it — +2.1% revenue is not a
        growth story on any reading; Valuation: did not rank it — the PEG of 3.11
        that failed the screen is not obviously wrong, just growth-dependent;
        Macro/Regime: neutral, no regime edge either way
STRONGEST CASE FOR: Fundamental/Quality's — the failure is on PEG alone, a
        growth-adjusted measure, and failing it says nothing about business
        quality. A screen rejecting a 59.8%-ROE business because one trailing year
        decelerated is the threshold measuring the wrong window, and naming that
        is a legitimate argument, not an override.
STRONGEST CASE AGAINST: The Contrarian's own admission, which I weight as heavily
        as its case: **forward P/E 13.25 sits above trailing 11.06.** Consensus
        expects earnings to *fall*, so this is not "the market is emotional and
        the estimates are fine" — it is a bet against the estimates themselves.
        Two voices are reading a four-year compounding record that the trailing
        four quarters already contradict. Agreement between them is not two pieces
        of evidence; it is the same series read twice.
DATA GAPS: (1) **No `sek_per_dkk` in this snapshot's macro block** — I cannot
        state a SEK price, a share count, or a position weight. That is an
        execution blocker, unchanged from yesterday. (2) The digest has no 52-week
        range, so I cannot say how beaten down it currently is — the core
        contrarian fact is unavailable. (3) No pipeline, patent-expiry or
        competitive data. Together these discount confidence by about two points.
CHAIRMAN CONVICTION: 6
MAJOR UNCERTAINTY: Is +2.1% trailing revenue a trough or a slope? One more
        reported quarter resolves it and nothing else will.
FINAL CALL: HOLD-WATCH — with two concrete unblocks, not an indefinite watch
PORTFOLIO-FIT REASONING: On fit this is arguably the best candidate in the
        universe — healthcare (one small position today), Denmark (Sweden is
        59.32%, ACT) and DKK (the individual sleeve is 100% SEK-quoted) in a
        single order. It still resolves to WATCH, and **not** because capital is
        short: (a) no SEK price can be computed, so no order can be sized —
        that alone is decisive; (b) tradeability on Avanza is presumed, not
        verified; (c) the growth question resolves by waiting one quarter at
        essentially no cost, because the portfolio already holds a defensive
        healthcare leg rather than a hole. Unblock conditions: a SEK/DKK rate in
        the fetcher or the workbook, **and** a reported quarter that does not
        deteriorate further. Then it leads the following contribution.
HORIZON: Long (3y+)
```

```
#5 OPPORTUNITY: TTE — TotalEnergies
TYPE: new candidate (not currently held)
AGENTS IN FAVOR: Macro/Regime: 5, the only real-asset hedge against the one shock
        (inflation re-acceleration at a ~+0.1% real policy rate) that would hit
        the equity and crypto sleeves simultaneously; Valuation: 4, P/E 11.05,
        forward 9.19, PEG 0.72, 4.78% dividend — the cheapest headline in the
        Passed list
AGENTS AGAINST / CAUTIOUS: Fundamental/Quality: did not pick it — ROIC 9.9% and
        margin 9.1% are mediocre against everything else on that list;
        Defensive/Risk: did not pick it — a cyclical commodity producer is not
        defence whatever its 0.062 beta says; Contrarian: did not pick it — it is
        cheap because the sector is structurally cheap, not because it is hated
STRONGEST CASE FOR: Macro/Regime's, and it is a portfolio-insurance argument
        rather than a return argument — energy is 0% of the book and it is the one
        sector positively levered to the correlated downside case.
STRONGEST CASE AGAINST: **A direct data conflict inside this system, which I am
        treating as decisive rather than smoothing over.** This sweep's digest
        reports revenue growth **+27.8%**; last sweep's full-JSON multi-year
        series for the same company showed **four consecutive declining fiscal
        years**. The Valuation voice set its own conviction at 4 because of it.
        A "cheap multiple on a growing business" thesis cannot be underwritten
        while the growth direction is internally contradicted by this system's own
        two reads of the same source.
DATA GAPS: The revenue-direction conflict above; no reserve life, no breakeven oil
        price, no capex plan; **no commodity-price data anywhere in this system**,
        so the macro hedging case is structural reasoning, not a view on oil;
        and the digest has no currency column, so it is not certain whether 88.33
        is USD (ADR) or EUR (Paris) — ~840 vs ~973 SEK/share. Heavy discount.
CHAIRMAN CONVICTION: 4
MAJOR UNCERTAINTY: Whether revenue is growing or shrinking. That is an
        embarrassingly basic thing not to know, and it is the finding.
FINAL CALL: NO ACTION — resolve the data conflict first
PORTFOLIO-FIT REASONING: The hole it fills is genuine (energy 0%, per `portfolio`)
        and the fit case is not the problem. The problem is that I will not fund a
        new position on a company whose revenue direction this system reports two
        different ways in two days. Concrete re-test: pull TTE's multi-year revenue
        series from the full screen JSON or the workbook next sweep. If revenue is
        genuinely growing at +27.8%, this moves up sharply; if the four-year
        decline is right, an 11x P/E is a sector feature and this drops out. Either
        way it is one data pull, not a judgement call.
HORIZON: Medium (6mo-3y)
```

---

### Other current-holding SELL calls that did not place in the Top 5

You get a direct answer to "should I sell anything" every sweep, not only when a
sell happens to rank.

| Holding | Flagged by | Chairman's call | Reasoning |
|---|---|---|---|
| **SHB-A.ST** | Fundamental (5), Valuation (5) | **SELL — fold into your next order round, do not make a special trip** | Two voices flag it, none defends it: revenue -3.8%, PEG 20.4, ROE 12.7%, ROA 0.63%, analyst "underperform", price at 96.0% of its range. The honest limit is that it is **one share worth 148.40 SEK (0.07% of the portfolio)** — courtage is a material fraction of the position. This is an attention-cost decision, not a return decision, and it is the third consecutive sweep it has been flagged. |
| **INVE-A.ST** | Contrarian (4) | **HOLD — but the reason is a data gap, not confidence** | At 91.1% of range with the "good upside" its own thesis named already captured, and the only metric that could test it — NAV discount/premium — has never been obtained (**S6**). The 4.73x P/E is a holding-company artifact, not cheapness. I will not recommend selling a position on the grounds that I cannot measure it, and I will not pretend that is the same as being comfortable. |
| **ALFA.ST** | Valuation (quality/price divergence, no SELL) | **HOLD — no adds** | PEG 2.86, the worst growth-adjusted value of the three P6 industrials despite the lowest headline P/E. But it scored highest of the three (63/100), with 10-of-10 real open-market insider buys and zero disposals since 2023, and four years of revenue growth with no down year. Expensive, not broken. |
| **ATCO-B.ST** | Valuation (quality/price divergence, no SELL) | **HOLD — no adds** | The divergence stated rather than averaged: Voice 1 rates the *business* top-tier (ROIC ~39.7%, best cash conversion in the sleeve); Voice 2 rates the *price* unattractive (P/E 32.6, PEG 2.38, 91.3% of range). Hold the quality; do not pay up for more of it. |
| **VOLV-B.ST** | none (risk flagged, no sell) | **HOLD** | TOO_EARLY — two weeks into a three-month break condition. Growth notes a genuine inflection (trailing revenue +2.7% after two declining fiscal years, -13.3% from the 2023 peak, forward P/E 13.76, analyst "buy"); Defensive flags D/E 147.3, the highest leverage in the book. Both are true; neither is actionable at two weeks. |
| **ethereum** | none | **HOLD — no adds** | Macro explicitly declined to recommend selling despite crypto being the one sleeve on the wrong side of this regime, and I agree: Fear & Greed 41 is mild fear and has *improved* from 31, the stated horizon is 3y+, and this system has no short-horizon edge. The no-adds freeze stands on **P1** — cost basis unknown, so any disposal is an uncomputable 30% K4 event and adding units makes a solvable record-keeping gap permanently harder. |
| **Valour Bitcoin Zero** | none | **HOLD** | INTACT, 0% fee, user-confirmed BTC-backed. Carried at cost because it still has **no price feed (S1)** — that is a pricing inconvenience, not a thesis problem, but it does mean this 9,183 SEK position (4.2% of the portfolio) cannot be repriced or drift-checked automatically. |
| **Avanza Global / Auto 3** | none | **HOLD** | Both INTACT. Avanza Global at 54.79% is a literal breach of the 15% single-position cap but is a diversified index fund, not idiosyncratic risk — weigh it as `portfolio` does. Fees 0.10% and 0.39%, both inside the 0.4% cap. |

**Also considered and not placed:** MSFT (Quality's honourable mention — a genuine
top-4 business, displaced only because Epiroc's marginal information value to this
specific book is higher), EPI-B.ST (Quality 6 — best Nordic-industrial quality
profile available, but forward P/E 37.96 above trailing 28.97 and it would add to
an ACT-rated 65.48% industrials sleeve), NVDA (Growth 6, arguing past a FAIL — the
threshold argument is sound, but macro downgrades it hardest and there is no order
book to underwrite it), UNH (Defensive 6 / Contrarian 6 — a real
margin-trough-versus-step-change question with a 3.1% margin providing very little
cushion, and no medical-loss-ratio data to resolve it), META (Valuation 6 / Growth
7 — the strongest forward-multiple compression in the universe, held back only by
the same DXY-118.90 currency point as GOOGL and by not being the best of the two),
VWS.CO (Growth 4, honest 4 — growth without returns on capital, ROIC 4.5%),
HEXA-B.ST and TEL2-B.ST (both explicitly rejected above, on forward-versus-trailing
P/E signatures).

---

## 3. Portfolio health scorecard

Carried over from the `portfolio` agent verbatim — not re-derived here.

| Dimension | Grade | Detail |
|---|---|---|
| Asset allocation vs targets | **WATCH** | Equity (look-through) **71.95%** vs 85% target, **-13.05pp**. Cash **16.75%** vs 5%, **+11.75pp** — but only ~11,183 ISK + 14,140 PayPal is genuinely deployable; hb-main is an earmarked tax reserve |
| Crypto allocation | **OK/WATCH** | **8.34%** vs 10% target — **underweight by 1.66pp**, not over |
| Equity sector concentration | **ACT** | Industrials **65.48%** of the individual-stock sleeve |
| Geography | **ACT** | Sweden **59.32%** |
| Currency exposure | **UNKNOWN** | No revenue-by-currency data exists for any holding |
| Market-cap tier (new) | **ACT** | **100% large-cap, zero mid- or small-cap** in the individual-stock sleeve — newly surfaced this sweep |
| Sustainability / ESG (new) | **UNKNOWN** | No ESG data exists for any held ticker |
| Single-position concentration | **ACT** | Avanza Global **54.79%** — a literal breach of the 15% cap, but a diversified index fund, not single-company risk; weigh accordingly |
| Institution concentration | **ACT** | Avanza **84.20%**, breaches the 80% cap — a byproduct of the (correct) ISK consolidation |
| Fee drag | **OK** | **0.084%**, far inside the 0.4% cap |
| Wrapper efficiency | **OK** | All capital in the ISK; ~115k SEK of headroom under the confirmed 300,000 SEK allowance |
| Drawdown-tolerance fit | **OK (provisional)** | The 2026-08-17 backtest stands (current mix -14.6%, adopted target -19.95%, both inside -30%). **No fresh backtest ran today** — this row is carried, not re-tested |

**The two new rows are the finding.** The market-cap row is the first time this
system has looked at tier and it comes back **100% large-cap with nothing in mid
or small**. That is not automatically wrong — large-cap is where the quality and
the data are — but it means every equity you own individually is exposed to the
same factor, on top of already being 65% one sector and 59% one country. Worth
knowing before the next contribution; **not worth fixing with a rushed small-cap
purchase**, and nothing in this sweep's universe was picked to fix it.

**Provisional on three unanswered `investor_profile.json` questions, named rather
than smoothed:**
- **Where is the emergency buffer held?** "3-6 months" is stated; the account is
  not. This decides whether the 11,363.76 SEK of Handelsbanken cash is buffer or
  investable capital — and therefore whether cash is really 16.75%.
- **`horizon.primary_goal` is explicitly uncertain, and the liability currency
  with it.** If the Mediterranean-apartment option firms up, the future liability
  is EUR, which reverses the rationale for any SEK/Nordic tilt entirely. That
  bears directly on how NOVO-B.CO and TTE should be weighted.
- **Currency exposure stays UNKNOWN.** The Defensive voice named this as the
  single metric that would most change its assessment at DXY 118.90.

**Structure (levers 1-2): nothing broke.** All capital is in the ISK, fee drag
0.084%. Reported in one line only, per the standing rule.

---

## Headline calls

Two from the Stock Selection Council, two from Portfolio Governance.

1. **Buy 3 shares of AZN.ST (~4,467 SEK) from the idle ISK cash — after the
   Riksbank decision on 2026-08-20.** Zero dissent across six independent lenses,
   which is uncommon; it re-affirms yesterday's call that did not execute, and the
   price moved +0.6%, not away from it. Confidence **High** · Horizon **Medium**.
2. **GOOGL is this sweep's best new opportunity and the largest available
   reduction in both the sector and geography concentrations — but it has no
   confirmed funding after call 1.** Route the PayPal conversion (P3, already
   decided) to it, or the next monthly contribution. Confidence **Medium** ·
   Horizon **Long**.
3. **Deploy the ISK cash after 2026-08-20, not before** — the Riksbank decision is
   two trading days away and this is a two-day wait with no carrying cost. See
   Governance A. Confidence **Medium** · Horizon **Short (tactical, ≤10% rule
   applies, never High confidence by policy)**.
4. **D4 still needs your answer, and it is no longer bookkeeping — it now decides
   how much of the 11,183 SEK is free to spend** (11,183 / ~7,917 / 0 depending on
   the reading). See Governance B for the three options. Confidence **High** that
   it needs deciding · Horizon **Long**.

---

## Portfolio Governance Council

*Non-stock decisions, so the five-voice method, not the six analyst lenses.*

### A — Deploy the 11,183 SEK ISK cash now, or wait through the Riksbank decision on 2026-08-20?

**The Contrarian.** The assumption everyone is making is that a two-day wait is
free. It usually is — but "wait for the event" is how idle cash stays idle: this
cash has now sat unspent through a full sweep because yesterday's buy was never
placed, and adding a second reason to wait is how a two-day deferral becomes a
two-week one.

**First Principles.** Strip the framing: the Riksbank sets the *krona*, and the
purchase under discussion (AZN.ST) is quoted in SEK and already owned. A rate
decision cannot reprice a SEK-quoted position you are adding to in SEK in any way
that a two-day wait protects you from — the exposure is identical on both sides of
the date. The collision `calendar` flagged is real for *international* deployment,
not for this one.

**The Expansionist.** Ignore the SEK constraint: the maximum-upside version is to
convert PayPal now, deploy the full ~24,700 SEK across AZN and GOOGL, and stop
managing the portfolio in 4,000 SEK increments — which points the same direction
as the modest version (deploy), just larger. Nothing in the expansive version
argues for waiting.

**The Outsider.** Described cold: "you have money sitting doing nothing, you have
decided what to buy, and you are waiting two days because a central bank you do
not lend to is meeting." That sounds like hesitation with a calendar attached
unless the purchase is currency-sensitive. For the SEK-quoted purchase it is not;
for a USD purchase it genuinely is.

**The Executor.** Monday: place 3 shares of AZN.ST. It is SEK-quoted, already
held, thesis intact, and the funding is confirmed idle.

**The Chairman.** The five voices split cleanly along one line — currency — and
that line is the answer, so this resolves into two different calls, not one
averaged one.

```
ACTION: BUY (SEK-quoted leg) — AZN.ST 3 shares, ~4,467 SEK, executable now;
        WAIT (foreign-currency leg) — any USD/DKK purchase until after 2026-08-20
POSITION: 11,183 SEK idle ISK cash = 5.11% of the full portfolio; cash overall
        16.75% vs a 5% target
TARGET: cash toward 5%; ISK cash below ~5,000 SEK after this round
REASON: (1) The Riksbank sets the krona, and the AZN leg is a SEK-quoted addition
        to a SEK-quoted position already held — the FX collision `calendar`
        flagged does not apply to it. (2) The GOOGL leg *is* currency-sensitive
        and is not funded this week anyway, so waiting costs nothing there.
        (3) Cash is the second-largest scorecard deviation and this money has
        already sat through one full sweep unspent.
THESIS STATUS: INTACT (AZN.ST); UNTESTED (the cash-deployment convention itself)
WHAT CHANGED: `portfolio` confirmed this sweep that yesterday's AZN buy did NOT
        execute and the 11,183 SEK is still idle — so this is a re-decision on
        live money, not a restatement.
BREAK CONDITION: If the 2026-08-20 Riksbank decision moves sek_per_usd more than
        ~3%, re-price the GOOGL leg before placing it rather than carrying this
        memo's share count forward.
CONFIDENCE: Medium (High on the merit; Medium because ~5,000 SEK of the 11,183
        traces to an Excel delta S9 flags as undocumented)
HORIZON: Short for the timing question; Medium for the position
```

### B — D4: does `profit_recycling_rule` apply to gross proceeds or only to the realized gain?

Presented again concisely as requested, not re-litigated. **This is now live
rather than academic: it decides how much of the 11,183 SEK you may spend.**

| Option | What it means | Trade-off | Cash freed |
|---|---|---|---|
| **1 — Target governs sizing; recycling governs only the surplus above target** *(Council's standing recommendation)* | Crypto is currently *under* target at 8.34%, so there is no surplus and nothing is owed to the secure tier | Most faithful to intent, but requires accepting that a written rule yields to a written target when they collide | **11,183 SEK** |
| **2 — Gross proceeds** | All 15,366 SEK of the COIN-XBT.ST sale belongs to the secure tier | Literal reading, but it would mechanically prevent crypto from ever returning to its 10% target after a full sale — and it implies your own Valour purchase was non-compliant, which your direct action outranks | **0 SEK** |
| **3 — Realized gain only** | 3,265.98 SEK to Avanza Global; the rest is free | Closest to the rule's own words ("the money I make from this"), and self-limiting | **~7,917 SEK** |

Every call in this memo is sized to survive options 1 and 3. **One sentence from
you closes it.**

---

## Where the agents disagreed

Foregrounded, not averaged.

1. **`portfolio` says crypto is UNDERWEIGHT; `macro-regime` says crypto is the one
   sleeve squarely on the wrong side of the regime.** Both are correct and they
   point opposite ways: allocation math says top up 1.66pp toward the 10% target,
   regime says do not add. **Resolution: no crypto adds.** Not because macro wins
   an argument, but because both crypto legs are independently blocked — ETH by
   **P1** (no cost basis, so every disposal becomes an uncomputable 30% K4 event
   and adding units makes it worse) and Valour by **S1** (no price feed, so you
   cannot size an addition against a live weight). A 1.66pp underweight is inside
   the noise of a position that cannot be priced. Confidence **High**.
2. **`valuation` describes VOLV-B.ST as having a "3rd straight year of revenue
   decline on trailing"; the snapshot's own four-year fiscal series shows two
   consecutive declines (2024, 2025, -13.3% from the 2023 peak) and trailing
   revenue growth of +2.7%.** Those are different claims about the direction of the
   business. The fetched series is the primary source and I am using it. Flagged
   for `journal` reconciliation because a lens describing a *positive* trailing
   figure as a third year of decline is the kind of drift that quietly hardens
   into a thesis. Confidence in the underlying data **High**; in the lens's
   summary **Low**.
3. **The same conflict, worse, on TTE:** this sweep's digest reports +27.8%
   revenue growth; last sweep's full JSON showed four consecutive declining fiscal
   years. This is a system-internal contradiction on the single fact the pick turns
   on, and it is why TTE resolves to NO ACTION rather than BUY. Confidence
   **Low** — deliberately, and the fix is one data pull.
4. **`macro-regime` downgrades GOOGL, META and NVDA purely on DXY 118.90 while
   Fundamental, Valuation and Growth rank them first, second and second
   respectively.** This is a currency-timing objection, not a business objection,
   and it is stated as such rather than buried in a lower conviction score. It is
   the reason GOOGL is #2 rather than #1 — and if you disagree with the regime
   read, the fundamental case is untouched. Confidence **Medium**.
5. **`thesis-review` holds ABB.ST at WEAKENING with an untested break condition;
   three of six voices call it a SELL on grounds that never touch that
   condition.** Second consecutive sweep with the same split. Resolved as
   HOLD-WATCH with a dated unblock (the FI insider pull before 2026-09-03),
   explicitly noting that ISK rotation is nearly frictionless so "selling is
   expensive" is not part of the reason. Confidence **Medium**.
6. **Equity reads 13.05pp under target while cash reads 11.75pp over — but the two
   do not net out the way that implies.** Roughly 11,364 SEK of the "excess" cash
   is an earmarked tax reserve and 14,140 SEK is PayPal that costs ~4% to move.
   The actionable gap is ~11,183 SEK, not ~25,700. Stated so the scorecard's
   allocation row is not read as a larger mandate than it is.

---

## Broken theses requiring a decision

**None.** `thesis-review` confirms every stored status unchanged: AZN.ST INTACT
(price ticked up slightly, 20.5th → 22.1st percentile of range, still below cost
basis); SHB-A.ST, INVE-A.ST, ATCO-B.ST, ALFA.ST and ABB.ST all still WEAKENING and
clustered 75-96% of their 52-week ranges with no differentiated theses; VOLV-B.ST
and the Valour certificate correctly TOO_EARLY. **No BROKEN calls.** The five
WEAKENING names are a standing condition, not a new event — and the honest
statement is that four of them share one undifferentiated thesis ("strong Swedish
industrial"), which is why the binding constraint on them is concentration (a
measurable fact) rather than valuation (an opinion).

---

## Rebalancing actions

| Action | Amount (SEK) | Source of funds | Timing |
|---|---|---|---|
| BUY AZN.ST, 3 shares @ ~1,489 | **~4,467** | Avanza ISK cash (11,183 idle, confirmed) | After 2026-08-20 |
| SELL SHB-A.ST, 1 share @ ~148 | **~148** | n/a — proceeds to ISK cash | Fold into the same order round; do not make a separate trip |
| BUY GOOGL, ~2 shares @ ~3,290 | **~6,580** | PayPal conversion (P3, ~13,575 SEK net) or next contribution | After P3 executes and after 2026-08-20 |
| Execute PayPal conversion + ISK transfer (P3) | ~14,140 gross, ~13,575 net (4% spread) | n/a | Any time; it is decided and pending only your action |
| No crypto action | 0 | — | Underweight 1.66pp, deliberately not corrected — see disagreement 1 |

Post-round, if all four execute: ISK cash falls to roughly 6,700 SEK before the
PayPal inflow, equity rises about 5.1pp toward the 85% target, industrials fall
from 65.48% to roughly 57% of the stock sleeve, and Sweden falls from 59.32%
toward ~56%.

---

## Cost of being wrong

| Call | If wrong, realistic downside | Recoverable? |
|---|---|---|
| BUY AZN.ST 3 sh (~4,467 SEK) | A 25% drawdown on the added shares ≈ **-1,117 SEK**; the full position at 8 shares would lose ~2,978 SEK on the same move | Yes — 2.0% of the portfolio, defensive name, no leverage, no tax event in the ISK |
| BUY GOOGL ~2 sh (~6,580 SEK) | A 35% drawdown (high-multiple, beta 1.24, plus a ~10% adverse USD move) ≈ **-2,300 SEK** | Yes — 3.0% of the portfolio; the currency leg is the part you cannot hedge here |
| SELL SHB-A.ST 1 sh | It continues to rise; forgone gain on 148 SEK is **≈ -30 SEK** on a further 20% move | Trivially |
| HOLD-WATCH ABB.ST rather than selling | If the valuation case is right and the multiple compresses 25%, **≈ -974 SEK** before the next FI pull | Yes — and the cost of waiting is bounded by the 2026-09-03 date |
| WAIT on TTE / NOVO-B.CO | Forgone entry if either re-rates upward in the interim; unquantifiable and deliberately not estimated | Yes — neither is a closing window |
| Deploy after 2026-08-20 rather than now | Two days of market movement on ~4,467 SEK; a 2% adverse move ≈ **-89 SEK** | Trivially |
| Not correcting the 1.66pp crypto underweight | ~3,636 SEK of exposure not held; if BTC/ETH rally 50%, forgone ≈ **-1,818 SEK** | Yes — and blocked by P1/S1 regardless |

---

## Timing collisions

- **Riksbank rate decision, 2026-08-20 — two trading days away.** `calendar`
  flags it against any near-term deployment: a decision repricing the krona lands
  before an international-equity purchase would settle. Carried onto the GOOGL
  call (wait) and explicitly *not* onto the AZN call (SEK-quoted, already held —
  see Governance A for why the distinction holds).
- **No holding has an earnings print inside the 45-day window.** Nothing else
  collides this sweep.

---

## Open actions vs open decisions

Pulled from `/OPEN_ITEMS.md`; referenced by ID, history not restated.

### Open actions — things you can just go do

| ID | Action | Amount / detail | By when |
|---|---|---|---|
| **P3** | Execute the PayPal conversion (decided: Option A, convert inside PayPal at the confirmed 4% spread) and transfer the SEK to the ISK | 1,177.49 USD + 266.88 EUR ≈ 14,140 SEK gross, ~13,575 net | No deadline, but it recurs every ~2 months — each delay repeats the cost |
| **S1** | Find the Valour Bitcoin Zero certificate's real Avanza ticker (verify on Avanza or by ISIN CH0585378661 — **do not guess it from the product name**) and add it to the Watchlist tab | — | Before next sweep if convenient; it blocks automated repricing of a 9,183 SEK position |
| **P6** | Run the next Finansinspektionen insider pull for ABB.ST | — | **Before 2026-09-03** — it is the stated unblock on the #3 call |
| **P1** | Dig up the ETH cost basis | — | Not urgent unless you intend to sell; it is what freezes the position |
| — | Place the trades in the Rebalancing table above | ~4,467 + ~148 SEK now; ~6,580 SEK after P3 | After 2026-08-20 |

### Open decisions — forks where the data does not pick one answer

| ID | Decision | Options |
|---|---|---|
| **D4 (S12)** | Does `profit_recycling_rule` apply to gross proceeds or the realized gain? | See the Governance B table: **(1)** target governs sizing → 11,183 SEK free *(Council's recommendation)*; **(2)** gross proceeds → 0 SEK free, and crypto can never return to target after a full sale; **(3)** realized gain only → 3,266 SEK to Avanza Global, ~7,917 free. |
| — | The unexplained **5,000 SEK** in the ISK cash figure | **(1)** Confirm it is the external transfer you described → the cash figure stands at 11,183; **(2)** check the Avanza statement and correct `portfolio.json` if it is an Excel artifact → the free figure drops to ~6,183 and call 2's funding must come entirely from PayPal. One statement check settles it. |
| — | Where is the emergency buffer held? | **(1)** It is the Handelsbanken 11,364 SEK → cash is genuinely 16.75% but ~5.2pp of that is untouchable, and the allocation row should be read against a smaller base; **(2)** it sits in Revolut / elsewhere outside the portfolio → the HB reserve is purely tax money and the cash overweight is smaller than graded. This is the single cheapest input that would sharpen the scorecard. |
| **S6** | Investor A NAV discount/premium — no free automated source | **(1)** Read NAV per share off Investor's IR page monthly and log it in the Excel Manual Data sheet → makes the position testable for the first time; **(2)** parse the quarterly report PDF with the `pdf` skill when you next have it → higher fidelity, more effort; **(3)** accept it stays untestable → then INVE-A.ST is held on faith, which should be a conscious choice rather than a default. |

---

## Excel data gaps

**No Excel import ran this sweep** — `data/cache/excel_import/latest-summary.json`
is still yesterday's (2026-08-17 11:11 UTC). Its five flags are unchanged and
already sit in `claude_excel_prompt.txt` (four missing 52-week ranges for
Nordic-primary tickers, treated as no-data and not blocking; and ATCO-B.ST's P/E
of 2.05, outside the 3-80 sanity range and still to be verified in the workbook —
**this system uses the fetched 32.6x, not the Excel figure**). Nothing new to fix
this sweep. The forward-looking requests are separate and are below.

---

## Consolidated Excel-improvement prompt

Appended as a dated block to `data/cache/excel_import/claude_excel_prompt.txt`
(items A-D from 2026-08-17 left intact, not duplicated). This sweep's new
requests, deduplicated across the six voices and `portfolio`:

- **E — currency column** on both STOCK DETAIL and the Watchlist tab. *Blocks:*
  the Valuation voice cannot compute an FCF yield because `fcf_b` and `mcap_b`
  are on different currency bases, and TTE cannot be sized because 88.33 might be
  USD or EUR.
- **F — an FX RATES block** (SEK per USD, EUR, **DKK**, NOK, CHF) via Excel's
  Currencies data type. *Blocks:* NOVO-B.CO and VWS.CO cannot be priced in SEK at
  all — this is the single most-repeated data request across two sweeps.
- **G — 52-week high/low on the Watchlist tab.** *Blocks:* the Contrarian voice's
  primary screen ran on seven holdings instead of 74 names.
- **H — NAV per share for Investor A** (and Latour) in the Manual Data sheet,
  from the monthly IR report. *Blocks:* S6, and with it any testable thesis for a
  2,032 SEK holding held at 91% of its range.

---

## Data-gap summary for `meta`

Rolled up from the six voices' per-pick flags plus `portfolio`'s own scope. Not
fixed here — surfaced for prioritisation.

1. **Swedish CPI stale at 2025M12 (S4) — third consecutive sweep capping a live
   call.** It now caps regime-grading of 59.32% of the portfolio's geography and
   65.48% of the stock sleeve. This has escalated from footnote to structural.
2. **No SEK/DKK rate** — blocks Novo Nordisk and Vestas from being sized at all,
   for the second sweep running. Smallest fix on this list with the largest
   immediate unblock.
3. **Currency inconsistency between `fcf_b` and `mcap_b` in the screen digest** —
   makes the FCF-yield proxy unusable, which matters because it is the stand-in
   for the missing EV/EBIT. Either normalise the currency or drop the field.
4. **No 52-week range in the digest** — disables the Contrarian voice's main
   triage field for every non-held name.
5. **No revenue-by-currency for any holding** — keeps the scorecard's currency row
   UNKNOWN, named by the Defensive voice as the single metric that would most
   change its assessment at DXY 118.90.
6. **No multi-year FCF/capex series** (structural Yahoo limit) — the specific gap
   behind unresolved calls on GOOGL, META and ABB.ST simultaneously.
7. **No look-through holdings for Avanza Global / Auto 3** — `portfolio` confirms
   the new industry/country/market-cap breakdown covers only the 7-stock sleeve,
   i.e. ~13% of the portfolio.
8. **No ESG/sustainability data for any held ticker** — the new scorecard row can
   only ever read UNKNOWN until a source exists.
9. **No commodity-price and no credit-spread data** — named by the Macro voice as
   the limits on its own energy and credit reasoning (V2 Phase 5).
10. **Fetch failures worth noting:** SAND (Sandvik), NDA-FI.ST (Nordea), NESN,
    NOVN, IWDA, VWCE, ACDVF.PA all returned 404 this sweep; `MC` resolved to
    something with a 4.9bn market cap in Financial Services, which is not LVMH —
    a probable ticker-resolution error worth checking.

---

## Learning notes

- **A forward P/E above the trailing P/E is the market telling you it expects
  earnings to fall — and it showed up four separate times this sweep, in
  opposite directions.** Trailing P/E divides today's price by the last twelve
  months of actual earnings; forward P/E divides it by next year's estimate. When
  forward is *higher*, the denominator is expected to shrink. Hexagon looks like
  the cheapest name in the whole screen at 10.85x until you see forward 17.68x —
  the trailing earnings contain something that is not repeating. Novo Nordisk at
  11.06 → 13.25 means buying it is a bet against the analysts' estimate, not just
  against sentiment, which is a materially harder bet. Epiroc shows the same
  signature (28.97 → 37.96). The reverse is equally informative: Meta at 21.41 →
  16.31 and Nvidia at 34.46 → 17.53 are consensus saying earnings are climbing
  fast. It costs nothing to check and it reorders a screen.
- **Inside an ISK, selling is almost free — which changes the bar for "hold."** In
  a taxable account, selling a winner triggers 30% on the gain, so "hold unless
  the case is overwhelming" is rational: the tax is a real cost of changing your
  mind. Inside an ISK there is no capital-gains event at all, only courtage
  (single-digit SEK on a position this size). So when this memo holds ABB.ST, the
  reason must be an actual argument about ABB — the untested break condition —
  and *not* the reflex that trading is expensive. Knowing which of your reasons
  are real and which are habits imported from a different tax wrapper is worth
  more than any single stock call.
- **Half of "ETH rose 0.7%" was the krona, not ethereum.** In euros ETH moved
  +0.09%. The SEK figure is larger because sek_per_eur went from 10.9523 to
  11.016 — the krona weakened about 0.58%, so the same euro-denominated asset is
  worth more kronor. Every foreign-currency holding you own carries this second
  engine, and it works both ways: it is exactly why the Macro voice objected to
  buying Alphabet with kronor at DXY 118.90. You would be taking a currency bet
  you were not paid to take, on top of an equity bet you were.
- **A screening threshold is a prior, not a verdict — but "I can argue the screen
  is wrong and still cannot underwrite this" is a legitimate stopping point.**
  Novo Nordisk failed `scout` on PEG 3.11 alone, a growth-adjusted measure that
  penalised one stalled year against four years of compounding — a fair criticism
  of the threshold. Nvidia failed on a trailing-P/E cap that mechanically rejects
  any company whose earnings are growing faster than its multiple. Both critiques
  are sound. Neither produced a BUY, because arguing a rule does not apply is only
  the first half; the second half is having the data to underwrite the company
  instead, and for Novo (no SEK/DKK rate, no pipeline data) that half is missing.
  Distinguishing "the screen is wrong here" from "therefore buy it" is most of the
  discipline.

---

*Run `journal` to log this sweep. An unlogged memo is invisible to the next
session and can never be reconciled — it is the only calibration mechanism this
system has.*
